Tuberculosis (Pulmonary)
Tuberculosis (TB) is a chronic granulomatous infection caused by the acid-fast bacillus Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can affect any organ system (extrapulmonary TB). TB exists in two clinical states: latent TB infection (LTBI), affecting approximately one-quarter of the global population, and active TB disease, which is symptomatic and infectious. Treatment requires prolonged combination chemotherapy to prevent resistance. Despite being curable, TB remains a leading cause of death from infectious disease worldwide, particularly in resource-limited settings and among immunocompromised individuals.
Clinical Pearls:
- One of the oldest known human diseases, still causing 1.3 million deaths annually
- Latent TB affects 25% of global population; 5-10% lifetime risk of reactivation
- "Night sweat" hallmark: Drenching sweats requiring sheet changes
- Sterile pyuria suggests renal TB (mycobacteria don't grow on standard culture)
- Vitamin D deficiency is a major risk factor for reactivation
Red Flags:
- Massive haemoptysis: Rasmussen's aneurysm (erosion into pulmonary artery)
- Meningeal signs: TB meningitis (high mortality if untreated)
- Spinal tenderness: Pott's disease (vertebral TB)
- Addisonian crisis: Adrenal TB causing adrenal insufficiency
- Miliary TB: Widespread dissemination, high mortality
TB remains a major global health problem despite being curable. Understanding epidemiology is crucial for diagnosis, prevention, and public health management.
Key Statistics:
- Global incidence: 10.6 million cases in 2022 (WHO)
- Global prevalence: 1.3 billion with latent TB (25% of population)
- Mortality: 1.3 million deaths in 2022
- Most affected: Southeast Asia (45%), Africa (25%), Western Pacific (18%)
- HIV co-infection: 6.3% of new TB cases globally
Geographic Distribution:
- High burden: India, China, Indonesia, Philippines, Pakistan, Nigeria
- Low burden: Most developed countries (less than 10 per 100,000)
- Resurgence: In some developed countries due to migration, HIV, drug resistance
Risk Groups:
- HIV infection: 20-30x increased risk of active TB
- Close contacts: 10-20% risk if exposed to active case
- Immunosuppressed: Organ transplant, anti-TNF therapy, steroids
- Socially deprived: Homelessness, substance use, incarceration
- Migrants: From high-prevalence areas
- Healthcare workers: Occupational exposure
Mortality and Morbidity:
- Case fatality: 5-10% in treated cases, 50-70% if untreated
- Drug-susceptible: >90% cure with appropriate treatment
- MDR-TB: 50-60% cure rate, higher mortality
- XDR-TB: 30-40% cure rate, very high mortality
TB results from infection with Mycobacterium tuberculosis, which evades host immunity through multiple mechanisms, leading to granuloma formation and potential reactivation.
Pathophysiology Steps:
-
Primary Infection: Inhalation of droplet nuclei containing M. tuberculosis. Bacilli are phagocytosed by alveolar macrophages but resist killing through cell wall components (cord factor, sulfatides)
-
Granuloma Formation: Infected macrophages recruit T-cells and other immune cells, forming granulomas (tubercles). The bacilli are contained but not eliminated, creating latent TB infection
-
Ghon Focus and Complex: Primary lesion in lung (Ghon focus) with hilar lymph node involvement (Ghon complex). Usually heals and calcifies, but bacilli remain viable
-
Latent TB Infection: Bacilli persist in granulomas in dormant state, controlled by host immunity. No symptoms, not infectious, but risk of reactivation
-
Reactivation: When immunity wanes (HIV, age, immunosuppression, malnutrition), granulomas break down. Caseous necrosis liquefies, creating cavities where bacilli multiply rapidly
-
Cavitation and Transmission: Cavitary lesions contain high bacterial load. Coughing aerosolizes bacilli, enabling transmission. Upper lobe predilection due to high oxygen tension
-
Dissemination: Bacilli can spread via bloodstream (miliary TB) or lymphatics to any organ, causing extrapulmonary TB (meninges, spine, kidneys, adrenals, etc.)
Non-Modifiable Risk Factors:
- Age: Infants and elderly at higher risk
- Genetics: Certain HLA types increase susceptibility
- Previous TB: History of TB increases reactivation risk
- Geographic origin: Born in or travel to high-prevalence areas
Modifiable Risk Factors:
- HIV infection: Strongest risk factor (20-30x increased risk)
- Immunosuppression: Organ transplant, anti-TNF therapy, steroids, chemotherapy
- Malnutrition: Protein-energy malnutrition, vitamin D deficiency
- Substance use: Alcohol, injection drug use
- Social factors: Homelessness, incarceration, overcrowding
- Diabetes: 2-3x increased risk
- Smoking: 2-3x increased risk
High-Risk Scenarios:
- Close contact: Household or workplace exposure to active TB
- Healthcare workers: Occupational exposure
- Prisoners: Overcrowding, high prevalence
- Refugees/migrants: From endemic areas
Protective Factors:
- BCG vaccination: Reduces risk of severe forms (miliary, meningitis) in children
- Good nutrition: Adequate protein, vitamin D
- HIV treatment: Antiretroviral therapy reduces TB risk
- Early diagnosis: Prompt treatment reduces transmission
Clinical presentation varies from asymptomatic (latent) to severe systemic illness (active disease). Symptoms develop insidiously over weeks to months.
Latent TB Infection:
Active Pulmonary TB:
Constitutional Symptoms:
Respiratory Symptoms:
Physical Signs:
Extrapulmonary TB:
Lymph Node (Scrofula):
Miliary TB:
TB Meningitis:
Spinal TB (Pott's Disease):
Other Sites:
Comprehensive examination identifies signs of active TB and assesses for complications. Serial examinations monitor treatment response.
General Examination:
- Appearance: Cachectic, ill-appearing
- Vital signs: Low-grade fever, tachycardia
- Weight: Document baseline, monitor during treatment
- Lymph nodes: Cervical, axillary, inguinal (scrofula)
Respiratory Examination:
- Inspection: May be normal, or signs of weight loss
- Palpation: Usually normal
- Percussion: May be dull if consolidation or effusion
- Auscultation: Apical crepitations (post-tussive), bronchial breathing if consolidation
- Clubbing: Late sign, indicates chronicity
Extrapulmonary Signs:
- Meningeal: Neck stiffness, Kernig's sign (TB meningitis)
- Spinal: Tenderness, kyphosis (Pott's disease)
- Abdominal: Masses, ascites (abdominal TB)
- Skin: Sinuses, scars (scrofula)
Complications Assessment:
- Respiratory failure: If extensive disease
- Massive haemoptysis: Emergency situation
- Neurological: If CNS involvement
- Adrenal insufficiency: If adrenal TB
Diagnostic evaluation confirms TB, identifies drug resistance, and assesses complications. Rapid diagnosis is essential for treatment and infection control.
Microbiological Diagnosis:
Sputum Examination:
- Samples: 3 sputum samples (including 1 early morning)
- Induction: If non-productive, use hypertonic saline nebulization
- Smear microscopy: Ziehl-Neelsen stain, detects acid-fast bacilli
- Sensitivity: 50-70% (requires high bacterial load)
- Rapid: Results within hours
Nucleic Acid Amplification:
- GeneXpert/Xpert MTB/RIF: Detects M. tuberculosis DNA and rifampicin resistance
- Sensitivity: 85-95% in smear-positive, 60-70% in smear-negative
- Rapid: Results in 2 hours
- Use: First-line test, guides initial treatment
Culture:
- Gold standard: Most sensitive test
- Media: MGIT (liquid) or Lowenstein-Jensen (solid)
- Time: 2-8 weeks for results
- Essential: For drug susceptibility testing
- Use: Confirms diagnosis, identifies resistance
Radiology:
Chest X-ray:
- Active TB: Upper lobe consolidation, cavitation, fibrosis
- Primary TB: Hilar lymphadenopathy, middle/lower lobe consolidation
- Miliary: Diffuse 1-2mm nodules throughout both lungs
- Healed: Calcified nodules, fibrotic changes
CT Chest:
- More sensitive: Detects early changes, small cavities
- Miliary: Better visualization of nodules
- Complications: Assesses extent, complications
Latent TB Screening:
Tuberculin Skin Test (TST/Mantoux):
- Method: Intradermal injection of PPD, read at 48-72 hours
- Interpretation: Induration size, considers BCG status, risk factors
- Limitations: False positives (BCG, NTM), false negatives (immunosuppression)
Interferon-Gamma Release Assays (IGRA):
- Tests: Quantiferon Gold, T-SPOT.TB
- Method: Blood test measuring interferon-gamma release
- Advantages: More specific than TST, not affected by BCG
- Use: Preferred in BCG-vaccinated individuals
Other Investigations:
- HIV test: Essential (high co-infection rate)
- Liver function: Baseline before treatment
- Renal function: Assesses for renal TB, guides dosing
- Complete blood count: May show anemia, leukocytosis
Drug Susceptibility Testing:
- Essential: For all culture-positive cases
- First-line: Rifampicin, isoniazid, pyrazinamide, ethambutol
- Second-line: If resistance suspected
- Rapid: GeneXpert detects rifampicin resistance
- Full DST: From culture, guides treatment
Management requires combination chemotherapy, directly observed therapy, and public health measures. Treatment duration and regimen depend on drug susceptibility.
TUBERCULOSIS MANAGEMENT ALGORITHM
==================================
Patient with suspected TB
|
v
Clinical Assessment + Investigations
|
+-------------------+-------------------+
| | |
ACTIVE TB LATENT TB NO TB
Confirmed (Positive TST/ (Negative
(Smear/PCR/ IGRA, normal screening)
Culture +) CXR, no symptoms)
| |
NOTIFY PUBLIC HEALTH LTBI Treatment
(Statutory) - Isoniazid 6-9m
ISOLATE OR
(Airborne - Rifampicin +
precautions) Isoniazid 3m
START RIPE OR
THERAPY - Rifampicin 4m
ACTIVE TB TREATMENT
|
+-------------------+-------------------+
| | |
DRUG-SUSCEPTIBLE MDR-TB XDR-TB
| | |
Standard 6-Month 18-24 Month Individualized
Regimen Regimen Regimen
| | |
Intensive Phase Second-line drugs Bedaquiline
(2 months): - Levofloxacin Delamanid
- Rifampicin - Moxifloxacin Linezolid
- Isoniazid - Bedaquiline Clofazimine
- Pyrazinamide - Delamanid - 18-24 months
- Ethambutol - Linezolid - Complex
- Clofazimine - High toxicity
- 18-24 months
Continuation Phase
(4 months):
- Rifampicin
- Isoniazid
MONITORING
|
+-------------------+-------------------+
| | |
Clinical Monitoring Laboratory Monitoring DOT
| | |
- Sputum conversion - LFTs (baseline, - Directly
at 2 months monthly) Observed
- Weight gain - Visual acuity Therapy
- Symptom resolution (ethambutol) - Ensures
- CXR improvement - Urate (pyrazinamide) adherence
- Side effects - FBC - Reduces
resistance
COMPLICATIONS MANAGEMENT
|
v
- Massive haemoptysis: Emergency management
- TB meningitis: Extended treatment, steroids
- Spinal TB: Surgical if needed
- Miliary TB: Extended treatment
- Drug toxicity: Adjust regimen
Standard Treatment (Drug-Susceptible TB):
Intensive Phase (2 months):
- Rifampicin: 10mg/kg (max 600mg) daily
- Isoniazid: 5mg/kg (max 300mg) daily + pyridoxine 25mg
- Pyrazinamide: 25-35mg/kg (max 2g) daily
- Ethambutol: 15-20mg/kg daily
- Monitoring: LFTs, visual acuity, urate
Continuation Phase (4 months):
- Rifampicin: 10mg/kg daily
- Isoniazid: 5mg/kg daily + pyridoxine
- Monitoring: Clinical response, sputum conversion
Directly Observed Therapy (DOT):
- Essential: Ensures adherence, prevents resistance
- Method: Healthcare worker observes each dose
- Frequency: Daily or 3x weekly (depending on regimen)
- Duration: Entire treatment course
Drug-Specific Monitoring:
Rifampicin:
- Side effects: Orange/red urine/tears (harmless), hepatitis, enzyme induction
- Monitoring: LFTs, drug interactions (OCP, warfarin)
Isoniazid:
- Side effects: Peripheral neuropathy, hepatitis
- Prevention: Pyridoxine 25mg daily
- Monitoring: LFTs, neurological symptoms
Pyrazinamide:
- Side effects: Gout (hyperuricemia), hepatitis, arthralgia
- Monitoring: Urate, LFTs
Ethambutol:
- Side effects: Optic neuritis (red-green color blindness, visual acuity loss)
- Monitoring: Visual acuity, Ishihara test, baseline and monthly
- Reversible: If caught early, stop immediately
MDR-TB Treatment:
- Duration: 18-24 months
- Regimen: Individualized based on DST
- Drugs: Fluoroquinolones, bedaquiline, delamanid, linezolid, clofazimine
- Monitoring: More intensive, higher toxicity
Latent TB Treatment:
- Isoniazid: 6-9 months (300mg daily)
- Rifampicin + Isoniazid: 3 months (shorter, better adherence)
- Rifampicin: 4 months (alternative)
- Indication: Positive TST/IGRA, no active disease, high risk of reactivation
TB can cause severe complications affecting multiple organ systems. Early recognition and treatment prevent morbidity and mortality.
Pulmonary Complications:
Massive Haemoptysis:
- Rasmussen's aneurysm: Erosion into pulmonary artery
- Management: Emergency bronchial artery embolization, may need surgery
- Mortality: High if not treated promptly
Respiratory Failure:
- Extensive disease: Bilateral involvement
- Management: Oxygen, may need ventilation
- Prognosis: Depends on extent and comorbidities
Pneumothorax:
- Ruptured cavity: Into pleural space
- Management: Chest drain, may be persistent
Extrapulmonary Complications:
TB Meningitis:
- High mortality: 20-50% even with treatment
- Neurological sequelae: Common in survivors
- Management: Extended treatment (9-12 months), steroids reduce mortality
- Hydrocephalus: May require shunting
Spinal TB (Pott's Disease):
- Vertebral collapse: Kyphosis, spinal deformity
- Neurological: Cord compression, paraplegia
- Management: Extended treatment, may need surgery
Miliary TB:
- Widespread: All organs affected
- High mortality: 20-30% even with treatment
- Presentation: Non-specific, often delayed diagnosis
Other:
- Adrenal TB: Addison's disease, adrenal crisis
- Renal TB: Renal failure, hypertension
- Pericardial TB: Constrictive pericarditis
- Bone/joint: Chronic osteomyelitis, joint destruction
Treatment-Related Complications:
Drug Toxicity:
- Hepatitis: From rifampicin, isoniazid, pyrazinamide
- Optic neuritis: From ethambutol (irreversible if not caught)
- Peripheral neuropathy: From isoniazid (prevent with B6)
- Gout: From pyrazinamide
Drug Resistance:
- MDR-TB: Resistant to rifampicin and isoniazid
- XDR-TB: MDR plus resistance to fluoroquinolones and injectables
- Causes: Inadequate treatment, poor adherence, drug quality issues
Prognosis is excellent with appropriate treatment for drug-susceptible TB. Drug-resistant TB has worse outcomes.
Drug-Susceptible TB:
- Cure rate: >90% with full treatment course
- Relapse: 2-5% (usually due to non-adherence)
- Mortality: less than 5% with treatment, 50-70% if untreated
- Time to sputum conversion: 2-3 months in most cases
MDR-TB:
- Cure rate: 50-60% with appropriate treatment
- Mortality: 10-20% during treatment
- Duration: 18-24 months of treatment
- Challenges: Drug toxicity, adherence, cost
XDR-TB:
- Cure rate: 30-40%
- Mortality: 20-30% during treatment
- Duration: 18-24 months, complex regimens
- Limited options: Few effective drugs available
Factors Affecting Prognosis:
- Early diagnosis: Better outcomes
- Adherence: Critical for cure and preventing resistance
- Drug susceptibility: Susceptible strains have better outcomes
- Comorbidities: HIV, malnutrition worsen prognosis
- Extent of disease: More extensive, worse prognosis
Major Guidelines:
- WHO Guidelines (2022): Treatment of tuberculosis
- NICE Guidelines (NG33, 2016): Tuberculosis
- ATS/CDC/IDSA Guidelines (2016): Treatment of drug-susceptible tuberculosis
- BTS Guidelines (2010): Tuberculosis in the UK
Landmark Clinical Trials:
-
British MRC Trials (1970s-1980s): Established short-course chemotherapy
- 6-month regimen as effective as 18-month
- RIPE combination highly effective
- Established current treatment standards
- PMID: Various historical
-
DOTS Strategy (1990s): Directly observed therapy
- Improves cure rates
- Reduces default rates
- Prevents drug resistance
- WHO recommended strategy
-
3HP Trial (2011): 3-month rifapentine-isoniazid for latent TB
- Non-inferior to 9 months isoniazid
- Better adherence
- Shorter duration
- PMID: 21632959
-
Bedaquiline Trials (2012-2013): New drug for MDR-TB
- Effective for MDR-TB
- Accelerates sputum conversion
- Improves outcomes
- PMID: 23339649
-
Delamanid Trials (2012): Another new MDR-TB drug
- Effective for MDR-TB
- Good safety profile
- Used in combination regimens
- PMID: 23075143
Meta-Analyses:
- Latent TB treatment: Isoniazid effective, shorter regimens non-inferior (Ziakas, 2013)
- MDR-TB treatment: Bedaquiline and delamanid improve outcomes (Caminero, 2017)
- DOT: Improves treatment success (Volmink, 2007)
Systematic Reviews:
- TB treatment: Comprehensive review of evidence (Nahid, 2016)
- Latent TB: Treatment options and efficacy (Ziakas, 2013)
- MDR-TB: Management strategies (Caminero, 2017)
"What is tuberculosis?" Tuberculosis (TB) is a bacterial infection that usually affects the lungs. It's caused by a germ called Mycobacterium tuberculosis. It's a serious infection that can make you very sick, but it's curable with the right treatment. TB spreads through the air when someone with active TB in their lungs coughs or sneezes.
"How did I get it?" TB spreads through tiny droplets in the air. If you were near someone with active TB who coughed, you could have breathed in the germs. Most people who get infected don't get sick right away - the germs stay "sleeping" in your body (latent TB). Later, if your immune system gets weaker, the germs can "wake up" and make you sick (active TB).
"What symptoms will I have?" The main symptoms are:
- A cough that won't go away (more than 3 weeks)
- Drenching night sweats (so bad you have to change your sheets)
- Losing weight without trying
- Feeling very tired all the time
- Fever, especially in the evenings
- Sometimes coughing up blood
"How is it diagnosed?" Your doctor will:
- Ask about your symptoms and if you've been around anyone with TB
- Test your sputum (phlegm) to look for the TB germs
- Do a chest X-ray to see if your lungs are affected
- Sometimes do a skin test or blood test to see if you've been exposed
"How is it treated?" TB needs special treatment with several strong antibiotics taken together for 6 months (or longer). You'll take:
- 4 different medicines for the first 2 months
- Then 2 medicines for the next 4 months
It's very important to take ALL your medicines, EVERY day, for the FULL time. If you stop early or miss doses, the TB can become resistant to the medicines, making it much harder to treat.
"Why so many medicines?" TB germs are very tough. Using just one medicine lets them learn to resist it. Using 4 medicines together makes sure we kill all the germs before they can become resistant. This is why you must finish the whole course.
"How long until I'm better?" Most people start feeling better within a few weeks of starting treatment. Your cough should get better, and you'll stop being infectious to others after about 2 weeks of treatment. However, you need to keep taking the medicines for the full 6 months to make sure all the germs are killed.
"Can I give it to others?" If you have active TB in your lungs, you can spread it to others by coughing. However, once you've been on treatment for 2 weeks, you're usually no longer infectious. Until then, you should:
- Stay home and avoid crowded places
- Cover your mouth when you cough
- Sleep in a separate room if possible
- Your doctor will tell you when it's safe to be around others
"What about side effects?" The medicines can cause side effects:
- Your urine and tears may turn orange/red (from rifampicin) - this is harmless
- You might feel sick to your stomach
- Your doctor will check your liver and eyes regularly
- Tell your doctor right away if you have vision problems, yellow skin, or severe side effects
"Will I be cured?" Yes! With proper treatment, more than 90% of people are completely cured. The key is:
- Taking all your medicines as prescribed
- Finishing the full course (don't stop early)
- Going to all your follow-up appointments
- Telling your doctor about any problems
"Can it come back?" If you finish your full treatment, it's very unlikely to come back (only 2-5% chance). If it does come back, it's usually because the treatment wasn't completed properly the first time. That's why it's so important to finish all your medicines.
"What if I miss doses?" Tell your doctor right away. Missing doses can let the TB germs become resistant to the medicines, making treatment much harder and longer. Your doctor may arrange for someone to watch you take your medicines (DOT - directly observed therapy) to make sure you don't miss any.
-
World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
-
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e195. PMID: 27516382
-
National Institute for Health and Care Excellence. Tuberculosis. NICE guideline [NG33]. 2016. Available at: https://www.nice.org.uk/guidance/ng33
-
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculin Skin Test and Interferon Gamma Release Assays. MMWR Recomm Rep. 2020;69(1):1-11. PMID: 32053584
-
Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011;133:257-266. PMID: 21441678
-
Frieden TR. Directly observed treatment, short-course (DOTS): ensuring cure of tuberculosis. Indian J Pediatr. 2000;67 Suppl 1:S21-S27. PMID: 11129903
-
Swaminathan S, Narendran G. Treatment of tuberculosis. Indian J Pediatr. 2000;67 Suppl 1:S28-S33. PMID: 11129902
-
Dheda K, Gumbo T, Maartens G, et al. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. Lancet Respir Med. 2017;5(4):291-360. PMID: 28344011
-
World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva: WHO; 2020.
-
Ziakas PD, Mylonakis E. Four months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49(12):1883-1889. PMID: 19929387
-
Menzies D, Long R, Trajman A, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008;149(10):689-697. PMID: 19017585
-
Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155-2166. PMID: 22150035
-
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med. 2009;360(23):2397-2405. PMID: 19494215
-
Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151-2160. PMID: 22670901
-
Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2007;(4):CD003343. PMID: 17943789
-
Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med. 1990;112(6):397-406. PMID: 2106815
-
Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-S279. PMID: 10529908
-
Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis. 2018;18(1):76-84. PMID: 29198911
-
Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014;(1):CD009593. PMID: 24448973
-
Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127-2135. PMID: 26017823